Literature DB >> 25754686

Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.

Gina S Ogilvie1,2, Monika Naus1,2, Deborah M Money1,3, Simon R Dobson1,4, Dianne Miller1,5, Mel Krajden1,2, Dirk J van Niekerk5, Andrew J Coldman5.   

Abstract

We report on the rates of cervical intraepithelial neoplasia (CIN) in young women aged 15-22 years of age in British Columbia before and after the introduction of an HPV vaccine program. Rates of cervical intraepithelial neoplasia (CIN) 2+ for each age stratum (15-22) in the calendar years 2004-2012 for the province of British Columbia were obtained from the BC Cancer Agency's population-based cervical cancer program. Incidence rate ratios (IRR) of CIN2+ were described and compared before and after HPV vaccine program introduction in cohorts born in vaccine eligible years, and in non-vaccine eligible years using piece-wise Poisson regression analysis, and adjusted for age. Between 2004 and 2012, rates of CIN2 and CIN2+ in young women aged 15-22 years in the province of British Columbia have decreased overall. After the introduction of the HPV vaccine program, the age adjusted IRR for CIN2+ for young women aged 15-17 years decreased significantly from 0.91 (95% CI: 0.86-0.98 p < 0.01) to 0.36 (95% CI: 0.18-0.73 p < 0.01). During the same time period, no similar reduction was found in young women 18-22 years. After introduction of HPV vaccine program, IRR for CIN2+ in young women 15-17 was significantly reduced for CIN2+ (0.14; 95% CI: 0.04- 0.47; p < 0.01) and CIN2 (0.1; 95% CI: 0.02-0.54; p < 0.01). This ecological analysis shows a significant reduction in CIN2+ lesions in young women aged 15-17 years in British Columbia after the introduction of the HPV vaccine in young women despite vaccine uptake levels below 70%.
© 2015 UICC.

Entities:  

Keywords:  HPV vaccine; cervical intraepithelial neoplasia; human papillomavirus; primary cancer prevention; vaccination program

Mesh:

Substances:

Year:  2015        PMID: 25754686     DOI: 10.1002/ijc.29508

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Starting cervical cancer screening at 25 years of age: the time has come.

Authors:  Cathy Popadiuk; Kathleen Decker; Cindy Gauvreau
Journal:  CMAJ       Date:  2019-01-07       Impact factor: 8.262

2.  Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015.

Authors:  Julia Warner Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Michelle L Johnson Jones; Erin Whitney; Manideepthi Pemmaraju; Monica Brackney; Nasreen Abdullah; Mary Scahill; Rebecca M Dahl; Angela A Cleveland; Elizabeth R Unger; Lauri E Markowitz
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

3.  Expression of p16INK4A in cervical precancerous lesions that is unlikely to be preventable by human papillomavirus vaccines.

Authors:  Suguna Badiga; Michelle M Chambers; Warner Huh; Isam-Eldin A Eltoum; Chandrika J Piyathilake
Journal:  Cancer       Date:  2016-08-01       Impact factor: 6.860

4.  Age-standardized cancer-incidence trends in Canada, 1971-2015.

Authors:  Darren R Brenner; Yibing Ruan; Eileen Shaw; Dylan O'Sullivan; Abbey E Poirier; Emily Heer; Paul J Villeneuve; Stephen D Walter; Christine M Friedenreich; Leah Smith; Prithwish De
Journal:  CMAJ       Date:  2019-11-18       Impact factor: 8.262

5.  Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.

Authors:  P Goggin; C Sauvageau; V Gilca; F Defay; G Lambert; S Mathieu-C; J Guenoun; E Comète; F Coutlée
Journal:  Hum Vaccin Immunother       Date:  2017-12-13       Impact factor: 3.452

6.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

7.  A community-based approach to cervical cancer prevention in western Kenya: An AMPATH feasibility project.

Authors:  Omenge Orang'o; Philip Tonui; Kapten Muthoka; Stephen Kiptoo; Titus Maina; Mercy Agosa; Aaron Ermel; Yan Tong; Darron Brown
Journal:  SAGE Open Med       Date:  2022-05-23

Review 8.  Mechanistic and Technical Challenges in Studying the Human Microbiome and Cancer Epidemiology.

Authors:  Mukesh Verma
Journal:  Technol Cancer Res Treat       Date:  2016-06-22

9.  Excisional Treatment of Cervical Dysplasia in Australia 2004-2013: A Population-Based Study.

Authors:  Gregory Robertson; Stephen J Robson
Journal:  J Oncol       Date:  2016-04-30       Impact factor: 4.375

10.  Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study.

Authors:  Samara Perez; Ovidiu Tatar; Gilla K Shapiro; Eve Dubé; Gina Ogilvie; Juliet Guichon; Vladimir Gilca; Zeev Rosberger
Journal:  BMC Public Health       Date:  2016-12-05       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.